The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

Pancreatic cancer is one of the deadliest types of cancer, with fewer than 13% of people diagnosed with it surviving for more ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...